1. National Heart and Lung Institute, Imperial College London, London, United Kingdom;
2. AstraZeneca, Cambridge, United Kingdom;
3. Department of Radiology and
4. Roy J. Carver Department of Biomedical Engineering, Medicine and Biomedical Engineering, University of Iowa, Iowa City, Iowa;
5. Royal Brompton Hospital, London, United Kingdom;
6. NIHR Nottingham Biomedical Research Centre,
7. Centre for Respiratory Research, NIHR Nottingham, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK;
8. ELEGI and COLT Laboratories, Queen’s Medical Research Institute, Edinburgh, United Kingdom;
9. Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom;
10. Belfast Health and Social Care Trust, Belfast, United Kingdom;
11. Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom;
12. Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom;
13. Faculty of Medicine, University of Southampton, Southampton, United Kingdom;
14. National Institute for Health and Care Research Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom;
15. AstraZeneca, Gothenburg, Sweden;
16. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany;
17. Chiesi Farmaceutici S.p.A., Parma, Italy;
18. GlaxoSmithKline, Brentford, United Kingdom;
19. Novartis Pharma AG, Basel, Switzerland; and
20. Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom